Affymax Takeda Collaboration and License Agreement
Phase 2b for anemia in dialysis, pre-dialysis and cancer chemotherapy patients
Structure:
Structure:
- Co-commercialize with equal profit sharing in the US
- Takeda commercializes outside the US
- Affymax supplies drug substance
- Affymax to receive M$105 upfront
- development and regulatory milestones to M$280
- commercial milestones to M$150
- jointly responsible for U.S. development costs; majority borne by Takeda
- outside US, Takeda bears development costs and pays a royalty on sales


0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home